Literature DB >> 21045203

Posttranscriptional regulation of PTEN dosage by noncoding RNAs.

Lin He1.   

Abstract

The classic "two-hit" model of tumor-suppressor inactivation, originally established by mathematical modeling of cancer incidence, implies that tumorigenesis requires complete loss of function of tumor-suppressor genes. Although this is true in some tumor types, the exact nature of tumor-suppressor deregulation varies depending on tissue type, stage of cancer development, nature of coexisting molecular lesions, and environmental factors. Emerging evidence has indicated the functional importance of PTEN (phosphatase and tensin homolog) dosage during tumor development. Among the key regulators of PTEN dosage are a number of noncoding RNAs, including microRNAs (miRNAs) and pseudogenes, which regulate PTEN abundance at the posttranscriptional level. Various studies have revealed the essential roles of these PTEN-targeting noncoding RNAs during tumor development, thus providing a paradigm to explore the molecular mechanisms underlying the dosage-dependent effects of key oncogenes and tumor suppressors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045203      PMCID: PMC4011638          DOI: 10.1126/scisignal.3146pe39

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  27 in total

Review 1.  The multiple roles of PTEN in tumor suppression.

Authors:  A Di Cristofano; P P Pandolfi
Journal:  Cell       Date:  2000-02-18       Impact factor: 41.582

Review 2.  Tumor suppressor genetics.

Authors:  Shannon R Payne; Christopher J Kemp
Journal:  Carcinogenesis       Date:  2005-09-08       Impact factor: 4.944

Review 3.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten.

Authors:  Peter T Jindra; Jessamyn Bagley; Jonathan G Godwin; John Iacomini
Journal:  J Immunol       Date:  2010-06-14       Impact factor: 5.422

5.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  PTEN loss accelerates KrasG12D-induced pancreatic cancer development.

Authors:  Reginald Hill; Joseph Hargan Calvopina; Christine Kim; Ying Wang; David W Dawson; Timothy R Donahue; Sarah Dry; Hong Wu
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

7.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

8.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

9.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.

Authors:  R C Lee; R L Feinbaum; V Ambros
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  21 in total

1.  Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer.

Authors:  Lei Nie; Hsing-Ju Wu; Jung-Mao Hsu; Shih-Shin Chang; Adam M Labaff; Chia-Wei Li; Yan Wang; Jennifer L Hsu; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2012-04-08       Impact factor: 4.060

2.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Authors:  Cuiling Liu; Javeed Iqbal; Julie Teruya-Feldstein; Yulei Shen; Magdalena Julia Dabrowska; Karen Dybkaer; Megan S Lim; Roberto Piva; Antonella Barreca; Elisa Pellegrino; Elisa Spaccarotella; Cynthia M Lachel; Can Kucuk; Chun-Sun Jiang; Xiaozhou Hu; Sharathkumar Bhagavathi; Timothy C Greiner; Dennis D Weisenburger; Patricia Aoun; Sherrie L Perkins; Timothy W McKeithan; Giorgio Inghirami; Wing C Chan
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

3.  miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression.

Authors:  Chandi Charan Mandal; Triparna Ghosh-Choudhury; Nirmalya Dey; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  Carcinogenesis       Date:  2012-06-07       Impact factor: 4.944

4.  NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation.

Authors:  Amit Bera; Nandini Ghosh-Choudhury; Nirmalya Dey; Falguni Das; Balakuntalam S Kasinath; Hanna E Abboud; Goutam Ghosh Choudhury
Journal:  Cell Signal       Date:  2013-08-24       Impact factor: 4.315

5.  Studying the Oncosuppressive Functions of PTENP1 as a ceRNA.

Authors:  Glena Travis; Nahal Haddadi; Ann M Simpson; Deborah J Marsh; Eileen M McGowan; Najah T Nassif
Journal:  Methods Mol Biol       Date:  2021

6.  Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Authors:  Martin D Forster; Konstantin J Dedes; Shahneen Sandhu; Sophia Frentzas; Rebecca Kristeleit; Alan Ashworth; Christopher J Poole; Britta Weigelt; Stan B Kaye; L Rhoda Molife
Journal:  Nat Rev Clin Oncol       Date:  2011-04-05       Impact factor: 66.675

7.  microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion.

Authors:  Nirmalya Dey; Falguni Das; Nandini Ghosh-Choudhury; Chandi Charan Mandal; Dipen J Parekh; Karen Block; Balakuntalam S Kasinath; Hanna E Abboud; Goutam Ghosh Choudhury
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

Review 8.  Novel classes of non-coding RNAs and cancer.

Authors:  Jiri Sana; Petra Faltejskova; Marek Svoboda; Ondrej Slaby
Journal:  J Transl Med       Date:  2012-05-21       Impact factor: 5.531

9.  Deletion of PTENP1 pseudogene in human melanoma.

Authors:  Laura Poliseno; Adele Haimovic; Paul J Christos; Eleazar C Vega Y Saenz de Miera; Richard Shapiro; Anna Pavlick; Russell S Berman; Farbod Darvishian; Iman Osman
Journal:  J Invest Dermatol       Date:  2011-08-11       Impact factor: 8.551

Review 10.  Phosphatase and Tensin Homologue: Novel Regulation by Developmental Signaling.

Authors:  Travis J Jerde
Journal:  J Signal Transduct       Date:  2015-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.